SEC Form SC 13G/A filed by Pediatrix Medical Group Inc. (Amendment)

$MD
Hospital/Nursing Management
Health Care
Get the next $MD alert in real time by email
SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 4 )*

            

Pediatrix Medical Group Inc


(Name of Issuer)

Common Stock


(Title of Class of Securities)

58502B106


(CUSIP Number)

December 31, 2023


(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[X] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[ ] Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


CUSIP No. 58502B106

1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

AllianceBernstein L.P.
13-4064930
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) [ ]
(b) [X]
3. SEC USE ONLY
4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5. SOLE VOTING POWER 6,852,567
6. SHARED VOTING POWER 0
7. SOLE DISPOSITIVE POWER 7,887,018
8. SHARED DISPOSITIVE POWER 0
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

7,887,018
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[X]
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.4%
12. TYPE OF REPORTING PERSON

IA




















Item 1.
(a) Name of Issuer
Pediatrix Medical Group Inc
(b) Address of Issuer's Principal Executive Offices
1301 CONCORD TERRACE, SUNRISE, FL 33323
Item 2.
(a) Name of Person Filing
AllianceBernstein L.P. ("AllianceBernstein L.P.")
(b) Address of Principal Business Office or, if None, Residence
501 Commerce Street, Nashville, TN 37203

All media outlets, please contact Jennifer Will at AllianceBernstein (212-969-1157) with any questions. All other questions can be directed to Section13USFilings@alliancebernstein.com.
(c) Citizenship
Delaware
(d) Title of Class of Securities
Common Stock
(e) CUSIP Number
58502B106
Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
(a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
(b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
(c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
(d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
Item 4. Ownership.
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount Beneficially Owned:
7,887,018 shares acquired solely for investment purposes on behalf of client discretionary investment advisory accounts.*
(b) Percent of Class:
9.4%
(c) Number of shares as to which such person has:
(i) sole power to vote or to direct the vote 6,852,567
(ii) shared power to vote or to direct the vote 0
(iii) sole power to dispose or to direct the disposition of 7,887,018
(iv) shared power to dispose or to direct the disposition of 0
*AllianceBernstein L.P. is a majority owned subsidiary of Equitable Holdings, Inc. ("EQH"). AllianceBernstein operates under independent management and makes independent decisions from EQH and its respective subsidiaries, and EQH calculates and reports beneficial ownership separately from AllianceBernstein pursuant to guidance provided by the Securities and Exchange Commission in Release Number 34-39538 (January 12, 1998).
Item 5. Ownership of Five Percent or Less of Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
Not Applicable
Item 8. Identification and Classification of Members of the Group.

Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
Item 9. Notice of Dissolution of Group.

Not Applicable
Item 10. Certification.

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AllianceBernstein L.P.
By: /s/ Melissa Guerra
Date: February 14, 2024
Name: Melissa Guerra
Title: Vice President

Get the next $MD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MD

DatePrice TargetRatingAnalyst
12/16/2024Outperform
Macquarie
9/26/2024$8.00 → $14.00Hold → Buy
Jefferies
6/7/2024$8.00Sell → Hold
Deutsche Bank
2/23/2022$32.00 → $31.00Outperform
Credit Suisse
12/22/2021$33.00 → $32.00Outperform
Credit Suisse
11/4/2021$29.00 → $27.00Market Perform
SVB Leerink
9/27/2021$29.00Market Perform
SVB Leerink
8/9/2021$30.00 → $32.00Neutral
Mizuho
More analyst ratings

$MD
Press Releases

Fastest customizable press release news feed in the world

See more
  • Pediatrix Medical Group Reports Fourth Quarter Results

    Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited

    $MD
    Hospital/Nursing Management
    Health Care
  • Pediatrix Medical Group to Host Premier Neonatology Conference Feb. 19-21

    As the preterm birth rate remains at an all-time high, continuing education for providers of neonatal intensive care is critical Pediatrix® Medical Group, Inc. (NYSE:MD), a leading provider of physician services, is pleased to announce NEO: The Conference for Neonatology, a premier educational event dedicated to advancing the field of neonatology. The conference will be held Feb. 19-21 in Las Vegas, Nevada, and will bring together neonatologists, pediatricians, advanced practitioners and allied health professionals from around the globe. As a trusted provider of neonatology services for more than 45 years, Pediatrix cares for nearly a quarter of the infants born in the United States tha

    $MD
    Hospital/Nursing Management
    Health Care
  • Pediatrix Medical Group 2024 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 20, 2025

    Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, February 20, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2024. A detailed press release will be issued the morning of February 20, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies

    $MD
    Hospital/Nursing Management
    Health Care

$MD
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MD
SEC Filings

See more

$MD
Leadership Updates

Live Leadership Updates

See more
  • Pediatrix Announces Strategic Initiatives For Enhanced Shareholder Value Creation

    Executive Chair Mark S. Ordan to Return as Chief Executive Officer Company Redoubles Strategic Focus on Physician Practices and Hospital and Health System Relationships Pediatrix Medical Group, Inc. (NYSE:MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today announced a leadership transition to accelerate its progress in executing a transformational strategy designed to create value for shareholders and other stakeholders. To best position Pediatrix to implement the strategy, which is based on recommitting to the highest standards in clinical excellence and strengthening the Company's hospital relationships, the Company's Board of Directors has appointed Ex

    $MD
    Hospital/Nursing Management
    Health Care
  • Pediatrix Board Appoints Sylvia Young as Independent Director

    Pediatrix Medical Group, Inc. (NYSE:MD), the nation's leading provider of highly specialized health care for women, children and babies, today announced that its board of directors has appointed Sylvia Young, a recognized leader in healthcare and long-term healthcare executive, as an independent director, effective May 12, 2023. Ms. Young, a veteran of hospital administration since 1985, most recently served as President and CEO of the HCA Continental Division, a multi-state regional healthcare system that is part of Hospital Corporation of America (HCA). Prior to her appointment to the Denver-based Division headquarters, Ms. Young served as President of HCA's Sunrise Health System, inclu

    $MD
    Hospital/Nursing Management
    Health Care
  • BurgerFi Appoints Vivian Lopez-Blanco to its Board of Directors

    PALM BEACH, Fla., July 15, 2021 (GLOBE NEWSWIRE) -- BurgerFi International, Inc. (NASDAQ:BFI, BFIIW))) ("BurgerFi" or the "Company"), one of the nation's fastest-growing premium fast-casual concepts, has appointed Vivian Lopez-Blanco to its board of directors, effective July 14, 2021. Lopez-Blanco's appointment follows the sudden passing of board member Steven Berrard announced on June 10, 2021. Lopez-Blanco has also been named as the chair of the audit committee and will be serving on the compensation committee and nominating governance committee. Lopez-Blanco is an experienced board member and seasoned finance executive with expertise in organizational transformations and driving prof

    $BFI
    $TAST
    $MD
    Restaurants
    Consumer Discretionary
    Hospital/Nursing Management
    Health Care

$MD
Financials

Live finance-specific insights

See more
  • Pediatrix Medical Group Reports Fourth Quarter Results

    Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.36 per share for the three months ended December 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.51. For the 2024 fourth quarter, Pediatrix reported the following results: Net revenue of $502 million; Net income of $30 million; and Adjusted EBITDA of $69 million. "Our strong fourth quarter results reflect continued top-line outperformance versus our expectations, the completion of our portfolio restructuring, and the related overhead expense reductions," said Mark S. Ordan, Chief Executive Officer of Pediatrix Medical Group. "I am honored and excited

    $MD
    Hospital/Nursing Management
    Health Care
  • Pediatrix Medical Group 2024 Fourth Quarter Conference Call/Webcast Scheduled for Thursday, February 20, 2025

    Pediatrix Medical Group, Inc. (NYSE:MD) will host an investor conference call and webcast on Thursday, February 20, 2025 at 9:00 a.m. ET to discuss results from operations for the quarter ended December 31, 2024. A detailed press release will be issued the morning of February 20, 2025 before the securities markets open. The investor conference call will be webcast and can be accessed at Pediatrix's website, www.pediatrix.com/investors. ABOUT PEDIATRIX MEDICAL GROUP Pediatrix® Medical Group, Inc. (NYSE:MD) is a leading provider of physician services. Pediatrix-affiliated clinicians are committed to providing coordinated, compassionate and clinically excellent services to women, babies

    $MD
    Hospital/Nursing Management
    Health Care
  • Pediatrix Medical Group Reports Third Quarter Results

    Pediatrix Medical Group, Inc. (NYSE:MD), a leading provider of physician services, today reported earnings of $0.23 per share for the three months ended September 30, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2024 third quarter, Pediatrix reported the following results: Net revenue of $511 million; Net income of $19 million; and Adjusted EBITDA of $60 million. "Our third quarter operating results modestly exceeded our expectations, driven primarily by strength in same-unit revenue," said James D. Swift, M.D., Chief Executive Officer of Pediatrix Medical Group. "During the quarter, we successfully completed our previously announced transition to a

    $MD
    Hospital/Nursing Management
    Health Care

$MD
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more